Overnight Market report, page-2371

Howdy Beady, personally I don't take a skerrick of notice of any of the Aussie biotech analysts in regard to immutep, they
invariably make a lot of money out of organising Immuteps CR's and have too much of an association with the company...
Let's just say they are too cosy with immutep for my liking......Cash runway till 2026?, it's still 2023, we must be gonna do nothing
for a couple of years......Goetz by far the best analyst immutep have in my opinion, but beware, there is still an association....
The way EFTI is progressing all of the above won't matter, it's just tying it down until the launch, and don't forget EFTI has
the potential to benefit a very broad base and addressable market, we just have to get the humans out of the way...And that's
not the patients I'm talking about...